Good cash flows from the launch of cholesterol-lowering drug Zetia in December could help Glenmark Pharma trim its debt significantly by the end of the year, says Pharma Analyst Surajit Pal of Prabhudas Lilladher.
Glenmark will enjoy 134 days of exclusivity from the launch of the drug.
Pal, however, believes Glenmark has reasonable growth outlook even on its core business ex-Zetia with its domestic formulations business reporting phenomenal performance in the second quarter.
He also shared his views on the scope of Renvela generic. He says it is an opportunity for multiple companies although as of now there is no proper guidance from US Food and Drug Administration (FDA) in terms of parameters that ne…